Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes

Treatment Use

Mobetron

Cancer Indication

Pancreatic

Number of Patients

158

Summary/Conclusion

A retrospective review of 158 patients who received IORT in the setting of biopsy-proven BR/LA PDAC following NAT between 2008 and 2017 was performed. The Kaplan–Meier method was used to analyze progression-free survival (PFS) and overall survival (OS) of FOLFIRINOX treated patients.

Read More

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial

Treatment Use

Mobetron

Cancer Indication

Pancreatic

Number of Patients

48

Summary/Conclusion

Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted.

Read More

Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery

Treatment Use

Electron IORT

Mobetron

Cancer Indication

Breast (Boost)

Number of Patients

71

Summary/Conclusion

The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation.

Read More

Accelerated Partial Breast Irradiation: Update of an ASTRO Evidence-Based Consensus Statement

Treatment Use

Electron IORT

Mobetron

Cancer Indication

Breast (Single-Fraction APBI)

Number of Patients

1000

Summary/Conclusion

Recently, interest has also grown in intraoperative radiation therapy (IORT), which treats the partial breast with a single dose of radiation using either low-energy x-rays or electrons, most commonly delivered at the time of surgery. These different modalities are likely to have certain tradeoffs with regard to their effectiveness and toxicity profiles, although these tradeoffs have yet to be completely described in the existing literature.

Read More

In vivo dosimetry with MOSFETs and GAFCHROMIC films during electron IORT for Accelerated Partial Breast Irradiation

Treatment Use

Electron IORT

Mobetron

Cancer Indication

Breast (Single-Fraction APBI)

Number of Patients

47

Summary/Conclusion

Authors AnnaPetoukhova, IrisRüssel, JulienneNijst-Brouwers, Kovan Wingerden, Jaapvan Egmond, DaphneJacobs, AndreasMarinelli, Joostvan der Sijp, PeterKoper, HenkStruikmans  Purpose The purpose of this study was to compare the delivered dose to the expected intraoperative radiation therapy (IORT) dose with in vivo dosimetry. For IORT using electrons in accelerated partial breast irradiation, this is especially relevant since a high dose is delivered in a single fraction. Methods For … Continued

Read More

Tinkle, C. et al., “Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.” (2015)

Treatment Use

Mobetron

Cancer Indication

Sarcoma

Number of Patients

26

Summary/Conclusion

This study demonstrates that incorporation of IORT as a component of multimodality management of patients with locally recurrent ESTS achieves high rates of local control and limb salvage with acceptable treatment morbidity and suggests that prior EBRT does not significantly influence disease control or toxicity. This technique offers a method of delivering focal therapy to achieve local control for the majority of patients who otherwise may require more radical surgical procedures.

Read More

Phillippson, C. et al., “Early Invasive Cancer and Partial Intraoperative Electron Radiation Therapy of the Breast: Experience of the Jules Bordet Institute.” (2014)

Treatment Use

Mobetron

Cancer Indication

Breast (Single-Fraction APBI)

Number of Patients

200

Summary/Conclusion

The preoperative diagnostic work-up must be comprehensive and the selection process must be rigorous for this therapeutic approach reserved for small ductal unifocal cancers. After 23.3 months median follow-up, the clinical results of IOERT for selected patients are encouraging for locoregional recurrence rate and toxicity rates. The satisfaction of our patients in terms of quality of life was extremely high.

Read More